{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:54:15Z","timestamp":1794491655353,"version":"4.9.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.antiviral.2019.104545","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T09:57:52Z","timestamp":1561456672000},"page":"104545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":153,"special_numbering":"C","title":["Antivirals targeting the polymerase complex of influenza viruses"],"prefix":"10.1016","volume":"169","author":[{"given":"Edin J.","family":"Mifsud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick G.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeron C.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.antiviral.2019.104545_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1086\/656316","article-title":"Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry","volume":"202","author":"Adisasmito","year":"2010","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104545_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2006\/165940","article-title":"The use of antiviral drugs for influenza: recommended guidelines for practitioners","volume":"17","author":"Allen","year":"2006","journal-title":"Can. J. Infect Dis. Med. Microbiol."},{"issue":"7","key":"10.1016\/j.antiviral.2019.104545_bib3","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza a H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.antiviral.2019.104545_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/v10110610","article-title":"Combination therapy with oseltamivir and favipiravir delays mortality but does not prevent oseltamivir resistance in immunodeficient mice infected with pandemic A(H1N1) influenza virus","volume":"10","author":"Baz","year":"2018","journal-title":"Viruses"},{"issue":"5983","key":"10.1016\/j.antiviral.2019.104545_bib5","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science (New York, N.Y.)"},{"issue":"3","key":"10.1016\/j.antiviral.2019.104545_bib6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"10.1016\/j.antiviral.2019.104545_bib7","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.antiviral.2019.104545_bib8","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/bcp.13733","volume":"84","author":"Deleu","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104545_bib9","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jac\/dkl376","article-title":"Use of neuraminidase inhibitors to combat pandemic influenza","volume":"58","author":"Democratis","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1086\/518936","article-title":"Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide","volume":"196","author":"Deyde","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"9979","key":"10.1016\/j.antiviral.2019.104545_bib11","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.antiviral.2019.104545_bib12","series-title":"5th Isirv-AVG Conference; Prevention and Treatment of RVIs: Antivirals, Traditional Therapies and Host-Directed Interventions","article-title":"Experience with favipiravir in phase 3 and implications for future studies","author":"Epstein","year":"2017"},{"issue":"7","key":"10.1016\/j.antiviral.2019.104545_bib13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial","volume":"219","author":"Finberg","year":"2018","journal-title":"J. Infect. Dis"},{"issue":"6","key":"10.1016\/j.antiviral.2019.104545_bib14","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1128\/jvi.68.6.4092-4096.1994","article-title":"The influenza virus panhandle is involved in the initiation of transcription","volume":"68","author":"Fodor","year":"1994","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1473-3099(13)70267-6","article-title":"Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial","volume":"14","author":"Fry","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104545_bib16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jac\/dky462","article-title":"Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection","volume":"74","author":"Fukao","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.antiviral.2019.104545_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. B"},{"issue":"3","key":"10.1016\/j.antiviral.2019.104545_bib18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib19","first-page":"e01217","article-title":"Determining the mutation bias of favipiravir in influenza using next-generation sequencing","volume":"93","author":"Goldhill","year":"2018","journal-title":"J. Virol."},{"issue":"45","key":"10.1016\/j.antiviral.2019.104545_bib20","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104545_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/375799","article-title":"High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza","volume":"188","author":"Goto","year":"2003","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104545_bib22","doi-asserted-by":"crossref","first-page":"1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1542\/peds.80.2.275","article-title":"Children with influenza a infection: treatment with rimantadine","volume":"80","author":"Hall","year":"1987","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.antiviral.2019.104545_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/infdis\/164.5.969","article-title":"Virulence of rimantadine-resistant human influenza a (H3N2) viruses in ferrets","volume":"164","author":"Hay","year":"1991","journal-title":"J. Infect. Dis."},{"issue":"25","key":"10.1016\/j.antiviral.2019.104545_bib25","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJM198912213212502","article-title":"Emergence and apparent transmission of rimantadine-resistant influenza a virus in families","volume":"321","author":"Hayden","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.antiviral.2019.104545_bib27","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1128\/AAC.35.9.1741","article-title":"Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine","volume":"35","author":"Hayden","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.antiviral.2019.104545_bib28","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104545_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2016.06.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015","volume":"132","author":"Hurt","year":"2016","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104545_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2009.03.003","article-title":"Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in oceania, south east Asia and South Africa","volume":"83","author":"Hurt","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104545_bib31","series-title":"Phase 3 Trial of Baloxavir Marboxil in High Risk Influenza Patients (CAPSTONE-2 Study). ID Week Advancing Science Week San Francisco","author":"Ison","year":"2018"},{"key":"10.1016\/j.antiviral.2019.104545_bib32","series-title":"Annual Scientific Conference for International Society for Influenza and Respiratory and Viral Disease","article-title":"Preclinical antiviral activity and ADME characteristics of the novel influenza endonuclease inhibitor AL-794. Options IX meeting","author":"Jekle","year":"2016"},{"key":"10.1016\/j.antiviral.2019.104545_bib33","series-title":"Susceptibility of Influenza Viruses to the Novel Cap-dependent Endonuclease Inhibitor Baloxavir Marboxil 6th Advances in Respiratory Virus Therapeutics","author":"Jones","year":"2018"},{"issue":"11","key":"10.1016\/j.antiviral.2019.104545_bib34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40261-018-0697-2","article-title":"Evaluation of drug\u2013drug interaction potential between baloxavir marboxil and oseltamivir in healthy subjects","volume":"38","author":"Kawaguchi","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"4","key":"10.1016\/j.antiviral.2019.104545_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/505868","article-title":"A comparison of the effectiveness of oseltamivir for the treatment of influenza a and influenza B: a Japanese multicenter study of the 2003\u20132004 and 2004\u20132005 influenza seasons","volume":"43","author":"Kawai","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.antiviral.2019.104545_bib36","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1086\/648424","article-title":"Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza a virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007\u20132008 and 2008\u20132009 influenza seasons","volume":"49","author":"Kawamura","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"9436","key":"10.1016\/j.antiviral.2019.104545_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.antiviral.2019.104545_bib38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/infdis\/jix606","article-title":"Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with influenza virus","volume":"217","author":"Kiso","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104545_bib39","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/j.ijid.2008.05.802","article-title":"T-705, a novel anti-influenza virus compound - the safety, tolerability and pharmacokinetics in human","volume":"12","author":"Kobayashi","year":"2008","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.antiviral.2019.104545_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40261-018-0710-9","article-title":"Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings","volume":"38","author":"Koshimichi","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.antiviral.2019.104545_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.02.007","article-title":"Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012\u20132018","volume":"164","author":"Koszalka","year":"2019","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104545_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0092-8674(79)90052-7","article-title":"Are the 5\u2032 ends of influenza viral mrnas synthesized in vivo donated by host mRNAs?","volume":"18","author":"Krug","year":"1979","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2019.104545_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016\u20132017","volume":"157","author":"Lackenby","year":"2018","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104545_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.bi.52.070183.002343","article-title":"The gene structure and replication of influenza virus","volume":"52","author":"Lamb","year":"1983","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.antiviral.2019.104545_bib46","series-title":"Hospital Recovery Scale- the Pimodivir Experience with an Ordinal Scale 6th ISIRV AVS Conference","author":"Leopold","year":"2018"},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/irv.12534","article-title":"Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study","volume":"12","author":"Lina","year":"2018","journal-title":"Influenza and Other Respir. Viruses"},{"issue":"3","key":"10.1016\/j.antiviral.2019.104545_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173582","article-title":"Identification of small molecule inhibitors for influenza a virus using in silico and in vitro approaches","volume":"12","author":"Makau","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.104545_bib49","doi-asserted-by":"crossref","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice","volume":"6","author":"Marathe","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.antiviral.2019.104545_bib50","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1021\/acs.jmedchem.5b00012","article-title":"A broad anti-influenza hybrid small molecule that potently disrupts the interaction of polymerase acidic protein\u2013basic protein 1 (PA-PB1) subunits","volume":"58","author":"Massari","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.104545_bib51","series-title":"\"Influenza Neuraminidase Inhibitors: Antiviral Action and Mechanisms of resistance.\" Influenza and Other Respiratory Viruses 7 Suppl 1(Suppl Suppl 1)","first-page":"25","author":"McKimm-Breschkin","year":"2013"},{"key":"10.1016\/j.antiviral.2019.104545_bib52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.antiviral.2017.11.013","article-title":"Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference","volume":"149","author":"McKimm-Breschkin","year":"2018","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.antiviral.2019.104545_bib53","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1086\/651605","article-title":"Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts","volume":"50","author":"Memoli","year":"2010","journal-title":"Clin. Infect. Dis. : Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2019.104545_bib54","series-title":"Report on the Deliberation Results","author":"Ministry of Health","year":"2018"},{"key":"10.1016\/j.antiviral.2019.104545_bib55","series-title":"Revisions of Precautions Baloxavir Marboxil","author":"Ministry of Health","year":"2019"},{"issue":"13","key":"10.1016\/j.antiviral.2019.104545_bib56","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.antiviral.2019.104545_bib57","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1073\/pnas.1119817109","article-title":"Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase","volume":"109","author":"Muratore","year":"2012","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104545_bib58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"The Lancet Respir. Med."},{"key":"10.1016\/j.antiviral.2019.104545_bib59","series-title":"Antiviral Resistance Surveillance in Japan (As of March 4 2019)","author":"National Institute of Infectious Diseases","year":"2019"},{"issue":"3","key":"10.1016\/j.antiviral.2019.104545_bib60","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2014.11.020","article-title":"Neuraminidase inhibitors: who, when, where?","volume":"21","author":"Nguyen-Van-Tam","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"issue":"12","key":"10.1016\/j.antiviral.2019.104545_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113633","article-title":"Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies","volume":"9","author":"Okoli","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.antiviral.2019.104545_bib62","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104545_bib63","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ajic.2016.09.024","article-title":"Oseltamivir for pandemic influenza preparation: maximizing the use of an existing stockpile","volume":"45","author":"Patel","year":"2017","journal-title":"Am. J. Infect. Contr."},{"issue":"4","key":"10.1016\/j.antiviral.2019.104545_bib64","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1128\/JVI.73.4.3473-3476.1999","article-title":"Direct evidence that the poly(A) tail of influenza a virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template","volume":"73","author":"Poon","year":"1999","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2019.104545_bib65","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbrc.2012.07.034","article-title":"Favipiravir (T-705) inhibits in vitro norovirus replication","volume":"424","author":"Rocha-Pereira","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.antiviral.2019.104545_bib66","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/INF.0b013e3181de9d24","article-title":"Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza a (H1N1) viruses with His275Tyr mutation","volume":"29","author":"Saito","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2019.104545_bib67","series-title":"XOFLUZATM (Baloxavir Marboxil) Tablets 10mg\/20mg for the Treatment of Influenza Types A and B Launched in Japan","author":"Shionogi","year":"2018"},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1620\/tjem.214.129","article-title":"Recurrence and persistence of fever in children who developed amantadine-resistant influenza viruses after treatment","volume":"214","author":"Shobugawa","year":"2008","journal-title":"Tohoku J. Exp. Med."},{"issue":"8","key":"10.1016\/j.antiviral.2019.104545_bib69","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/656408","article-title":"Early oseltamivir treatment of influenza in children 1\u20133 Years of age: a randomized controlled trial","volume":"51","author":"Silvennoinen","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104545_bib70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.antiviral.2019.104545_bib71","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med. Res. Rev."},{"issue":"45","key":"10.1016\/j.antiviral.2019.104545_bib72","doi-asserted-by":"crossref","first-page":"19151","DOI":"10.1073\/pnas.1013592107","article-title":"High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity","volume":"107","author":"Su","year":"2010","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104545_bib73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10156-011-0288-0","article-title":"Widespread use of neuraminidase inhibitors in Japan","volume":"17","author":"Sugaya","year":"2011","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.antiviral.2019.104545_bib74","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir","volume":"132","author":"Takashita","year":"2016","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104545_bib75","doi-asserted-by":"crossref","first-page":"1800698","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800698","article-title":"Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill."},{"issue":"12","key":"10.1016\/j.antiviral.2019.104545_bib76","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2019.104545_bib77","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.02.003","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013\u20132014","volume":"117","author":"Takashita","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104545_bib78","series-title":"AVIGAN Tablets","author":"Toyama Chemical","year":"2018"},{"issue":"8","key":"10.1016\/j.antiviral.2019.104545_bib79","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial","volume":"283","author":"Treanor","year":"2000","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2019.104545_bib80","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.104545_bib81","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz244","article-title":"Treatment emergent influenza virus variants with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","author":"Uehara","year":"2019","journal-title":"JID (J. Infect. Dis.)"},{"key":"10.1016\/j.antiviral.2019.104545_bib82","series-title":"Inhibitor of Cap\u2010dependent Endonuclease of Influenza A and B Virus, Leads to Rapid and Profound Viral Load Reduction. Options for the Control of Influenza","author":"Uehara","year":"2016"},{"key":"10.1016\/j.antiviral.2019.104545_bib83","author":"US Food and Drug Administration"},{"key":"10.1016\/j.antiviral.2019.104545_bib84","series-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza","author":"Uyeki","year":"2018"},{"issue":"10","key":"10.1016\/j.antiviral.2019.104545_bib85","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/cix127","article-title":"Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis","volume":"64","author":"Venkatesan","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib86","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"9","key":"10.1016\/j.antiviral.2019.104545_bib87","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors, 2008\u20132011: the influenza resistance information study (IRIS)","volume":"56","author":"Whitley","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104545_bib88","series-title":"Overview of RSV and Influenza Programmes. International Society for Influenza and Other Respiratory Virus Diseases -Advances in Respiratory Viral Therapeutics","author":"Witek","year":"2018"},{"key":"10.1016\/j.antiviral.2019.104545_bib89","series-title":"Standard Guidelines for the Clinical Management of Severe Influenza Virus Infections Initial Guideline Development Group (GDG) Meeting","author":"World Health Organisation","year":"2018"},{"issue":"2","key":"10.1016\/j.antiviral.2019.104545_bib90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/infdis\/jiy410","article-title":"Antiviral activity, safety, and pharmacokinetics of AL-794, a novel oral influenza endonuclease inhibitor: results of an influenza human challenge study","volume":"219","author":"Yogaratnam","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.antiviral.2019.104545_bib91","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/650581","article-title":"Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection","volume":"50","author":"Zheng","year":"2010","journal-title":"Clin. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219301950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219301950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:34Z","timestamp":1759062574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219301950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":91,"alternative-id":["S0166354219301950"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104545","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antivirals targeting the polymerase complex of influenza viruses","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104545"}}